Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 259

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 10
Chunk 259
---
1 clinical trial in humans in relapsed of refractory AML with IPH6101/SAR443579, respectively in January and December 2021.

In April 2024, Sanofi advanced SAR’579 / IPH6101, to the Phase 2 preliminary dose expansion of the trial. Under the terms of the research collaboration and licensing agreement, the progression to the dose expansion part of the trial triggered a milestone payment from Sanofi to Innate of €4 million.

On April 23, 2025, the Company announced that, in alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Agreement as it relates to SAR’579/IPH6101 (CD123 ANKET®), effective as of June 30, 2025. Innate will regain its rights on July 1, 2025.

IPH6401

In July 2022, the Company announced that Sanofi has made the decision to progress IPH6401/SAR’514 into investigational new drug (IND) enabling studies, triggering a €3 million milestone payment.

On July 11, 2023, the Company announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial (NCT05839626), evaluating SAR’514 / IPH6401 in relapsed/refractory multiple myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA). SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on the Company’s ANKET® proprietary platform. The purpose of the dose escalation and dose expansion study is to evaluate the safety, pharmacokinetics and preliminary efficacy of SAR’514 in monotherapy in patients with RRMM and RRLCA. The start of the trial has triggered a milestone payment from Sanofi to Innate, which is part of a previously announced research collaboration

with Sanofi. More information about the Phase 1/2 trial, see “ Item 4. B - Business Overview - IPH6401/SAR’514, a BCMA-targeting NK Cell Engager.”

The Company announcedon